COVID-19
RAPID ANTIGEN & ANTIBODY TESTING POST-VACCINATION

Receive your rapid antigen and spike protein antibody test for the novel coronavirus ("SARS-CoV-2") infection known as COVID-19.

RAPID ANTIGEN COVID-19 TESTING
Rapid Antigen Testing is recommended if you are experiencing fever, cough, shortness of breath, difficulty breathing, or if you had contact with someone that has COVID-19. Testing can provide a positive or negative test result within 15 minutes.

SPIKE PROTEIN ANTIBODY TESTING
Determine if there is a level of IgG antibodies that may provide protection after receiving vaccination.

Roslyn High School
May 22 and May 23, 2021, 9am - 5pm
475 Round Hill Rd, Roslyn Heights, NY 11577
Antibody Testing Link: https://roslynantibody523.youcanbook.me/
Rapid Testing Link: https://roslynrapid523.youcanbook.me/

** All insurance accepted and those uninsured are welcomed under The CARES Act **

Advanced Cardiovascular Diagnostics  In a heartbeat, we could save your life.
(516) 488-5050  info@cardiovasculartesting.com  CardiovascularTesting.com
COVID-19 POST VACCINATION
Receive your spike protein antibody test for the novel coronavirus ("SARS-CoV-2") infection known as COVID-19

SPIKE PROTEIN ANTIBODY TESTING
NEWS FLASH
HAS YOUR VACCINE PRODUCED ANTIBODIES?

- Are you seeking reassurance that your Covid-19 Vaccine is working?
- A new "spike protein antibody test" can be used to determine if your body has produced antibodies after receiving a vaccine.
- With a simple blood draw, the test searches for spike proteins which present themselves after receiving your Covid-19 Vaccine.
- Determine if there is a level of IgG antibodies that may be protective after receiving vaccination.
- Wait two weeks post-vaccination and receive your results in 24 to 48 hours to determine your levels of antibodies.


**This test has been approved under FDA Emergency Use Authorization**

Advanced Cardiovascular Diagnostics  In a heartbeat, we could save your life.
(516) 488-5050  info@cardiovasculartesting.com  Cardiovasculartesting.com
FIGHTING THE CORONAVIRUS PANDEMIC DRIVES YOU. DELIVERING HIGH-QUALITY ASSAYS DRIVES US.

Beckman Coulter offers a set of COVID-19 tools with high medical value to determine active infection and adaptive immune response. Together, the SARS-CoV-2 IgM assay and SARS-CoV-2 IgG assay provide a clearer picture of a COVID-19 patient’s immune status.

A New Assay in the COVID-19 Toolbox

Access SARS-CoV-2 IgG II is a semi-quantitative assay that measures a patient’s level of antibodies in response to a previous SARS-CoV-2 infection providing a numerical result in Arbitrary Units (AU) from 2.00 - 450 AU/mL and a qualitative result reported as non-reactive (<10AU/mL) or reactive (≥10AU/mL) to SARS-CoV-2.

With a semi-quantitative COVID-19 IgG antibody assay, clinicians can:

› Establish a baseline to evaluate an individual’s immune response based on a numerical value
› Assess relative changes of an individual’s immune response to the SARS-CoV-2 virus over time
› Assess whether there is a level of IgG antibodies that may be protective

Always quality first

› The positive percent agreement (PPA) of the Access SARS-CoV-2 IgG II assay is 96.0% at 8-14 days post symptom onset
› The overall negative percent agreement (NPA) of the Access SARS-CoV-2 IgG assay is 99.9% evaluated in a study with 1,448 samples

“We selected the Beckman Coulter Access SARS-CoV-2 IgG antibody assay to be the backbone of Henry Ford’s COVID-19 serologytesting program because of its outstanding performance in our rigorous independent evaluation,”

—Dr. Bernard C Cook, Division Head of Chemistry-Pathology, Henry Ford Health System.
Deliver results with a high medical value

This new assay offers the same level of quality as our other SARS-CoV-2 IgG and IgM serology tests. All of the Beckman Coulter COVID-19 antibody assays target the RBD of the spike protein, as it is critical for viral entry and has shown to be neutralizing in a surrogate model.

Beckman Coulter selected the receptor-binding domain (RBD) of the S1 spike antigen to detect antibodies that block the virus entry into the cells. This selection is aligned with the multiple vaccines in development that target or include the SARS-CoV-2 RBD S1 used in our assay, with the goal of producing protective antibodies.

Seamless integration for improved lab efficiency

› Integrate the assay seamlessly into your routine laboratory workflow
› Run in random access mode (RAM) without the need for batching or special maintenance
› Run up to 200 tests per hour depending on the analyzer used (for example, with DxI 800, labs can

Ordering information

| ACCESS SARS-CoV-2 IgG II Reagent Kit 200 tests/kit (2 packs, 100 tests/pack) | C69057 |
| ACCESS SARS-CoV-2 IgG II Calibrators (50-55, 6 levels, 1 vial/level, 2 mL/vial) | C69058 |
| ACCESS SARS-CoV-2 IgG II Quality Control (QC1-QC2, 2 levels, 3 vials/level, 4 mL/vial) | C69059 |

References

1. The result will be displayed as non-reactive (<10 AU/mL) and reactive (>/>=10 AU/mL).
2. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity.

All data are based on the Access SARS-CoV-2 IgG II Assay Instructions for Use (C69152)